Skip to content Accessibility tools

DOH Advisory: Updates to COVID-19 Treatment Recommendations

This announcement is to make you aware of updates to COVID-19 treatment recommendations. Emerging omicron subvariants (e.g., BQ.1 and BQ.1.1) are resistant to the monoclonal antibodies (mAbs) bebtelovimab and Evusheld (authorized for pre-exposure prophylaxis). On November 30, 2022, the FDA updated the Emergency Use Authorization (EUA) fact sheet https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region for the COVID-19 monoclonal antibody bebtelovimab. Due to the prevalence of Omicron sub-variants such as BQ.1/BQ.1.1, bebtelovimab is not currently authorized for emergency use in the U.S.

For questions, please send an e-mail to COVID19therapeutics@health.ny.gov.

NYSHFA/NYSCAL CONTACTS:

Lisa Volk, RN, B.P.S., LNHA
Director, Clinical & Quality Services
518-462-4800 x15

Jackie Pappalardi, RN, BSN
Executive Director
518-462-4800 x16